Mixed connective tissue disease

Robert W. Hoffman, Eric L Greidinger

Research output: Contribution to journalArticle

53 Citations (Scopus)

Abstract

A defining feature of mixed connective tissue disease (MCTD) is the presence of antibodies against the U1-ribonucleoprotein (RNP) complex, but other autoantibodies in MCTD have recently been described. Research has also further elucidated the immune responses directed against U1-RNP in humans and in murine models of disease. Hypotheses implicating modified self-antigens and/or infectious agents in the pathogenesis of MCTD have been advanced. Links between the immunologic and clinical phenomena in MCTD are emerging. Longitudinal study of patients with MCTD highlights the impact of pulmonary hypertension on disease outcome. (C) 2000 Lippincott Williams and Wilkins, Inc.

Original languageEnglish
Pages (from-to)386-390
Number of pages5
JournalCurrent Opinion in Rheumatology
Volume12
Issue number5
DOIs
StatePublished - Sep 18 2000
Externally publishedYes

Fingerprint

Mixed Connective Tissue Disease
Ribonucleoproteins
Autoantigens
Pulmonary Hypertension
Autoantibodies
Longitudinal Studies
Antibodies
Research

ASJC Scopus subject areas

  • Rheumatology
  • Immunology

Cite this

Mixed connective tissue disease. / Hoffman, Robert W.; Greidinger, Eric L.

In: Current Opinion in Rheumatology, Vol. 12, No. 5, 18.09.2000, p. 386-390.

Research output: Contribution to journalArticle

Hoffman, Robert W. ; Greidinger, Eric L. / Mixed connective tissue disease. In: Current Opinion in Rheumatology. 2000 ; Vol. 12, No. 5. pp. 386-390.
@article{eba20a84c0114f5a9b68490d25bd65cd,
title = "Mixed connective tissue disease",
abstract = "A defining feature of mixed connective tissue disease (MCTD) is the presence of antibodies against the U1-ribonucleoprotein (RNP) complex, but other autoantibodies in MCTD have recently been described. Research has also further elucidated the immune responses directed against U1-RNP in humans and in murine models of disease. Hypotheses implicating modified self-antigens and/or infectious agents in the pathogenesis of MCTD have been advanced. Links between the immunologic and clinical phenomena in MCTD are emerging. Longitudinal study of patients with MCTD highlights the impact of pulmonary hypertension on disease outcome. (C) 2000 Lippincott Williams and Wilkins, Inc.",
author = "Hoffman, {Robert W.} and Greidinger, {Eric L}",
year = "2000",
month = "9",
day = "18",
doi = "10.1097/00002281-200009000-00006",
language = "English",
volume = "12",
pages = "386--390",
journal = "Current Opinion in Rheumatology",
issn = "1040-8711",
publisher = "Lippincott Williams and Wilkins",
number = "5",

}

TY - JOUR

T1 - Mixed connective tissue disease

AU - Hoffman, Robert W.

AU - Greidinger, Eric L

PY - 2000/9/18

Y1 - 2000/9/18

N2 - A defining feature of mixed connective tissue disease (MCTD) is the presence of antibodies against the U1-ribonucleoprotein (RNP) complex, but other autoantibodies in MCTD have recently been described. Research has also further elucidated the immune responses directed against U1-RNP in humans and in murine models of disease. Hypotheses implicating modified self-antigens and/or infectious agents in the pathogenesis of MCTD have been advanced. Links between the immunologic and clinical phenomena in MCTD are emerging. Longitudinal study of patients with MCTD highlights the impact of pulmonary hypertension on disease outcome. (C) 2000 Lippincott Williams and Wilkins, Inc.

AB - A defining feature of mixed connective tissue disease (MCTD) is the presence of antibodies against the U1-ribonucleoprotein (RNP) complex, but other autoantibodies in MCTD have recently been described. Research has also further elucidated the immune responses directed against U1-RNP in humans and in murine models of disease. Hypotheses implicating modified self-antigens and/or infectious agents in the pathogenesis of MCTD have been advanced. Links between the immunologic and clinical phenomena in MCTD are emerging. Longitudinal study of patients with MCTD highlights the impact of pulmonary hypertension on disease outcome. (C) 2000 Lippincott Williams and Wilkins, Inc.

UR - http://www.scopus.com/inward/record.url?scp=0033839871&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0033839871&partnerID=8YFLogxK

U2 - 10.1097/00002281-200009000-00006

DO - 10.1097/00002281-200009000-00006

M3 - Article

C2 - 10990174

AN - SCOPUS:0033839871

VL - 12

SP - 386

EP - 390

JO - Current Opinion in Rheumatology

JF - Current Opinion in Rheumatology

SN - 1040-8711

IS - 5

ER -